Dexamethasone 12 mg Versus 6 mg for Patients with COVID-19 and Severe Hypoxia: An International, Randomised, Blinded Trial - Marie Warrer Munch, M. W. Munch, K. la Cour, Sheila Nainan Myatra, B. Kumar Tirupakuzhi Vijayaraghavan, Sanjith Saseedharan, Thomas Benfield, Rebecka Rubenson Wahlin, R. R. Wahlin, Bodil Steen Rasmussen, B. S. Rasmussen, Anne Sofie Andreasen, Lone M. Poulsen, L. M. Poulsen, Luca Cioccari - Dissemin

Dissemin is shutting down on January 1st, 2025

Language
Login

Published in

SSRN Electronic Journal, 2021

DOI: 10.2139/ssrn.3884949

Links

Tools

Export citation

Search in Google Scholar

Dexamethasone 12 mg Versus 6 mg for Patients with COVID-19 and Severe Hypoxia: An International, Randomised, Blinded Trial

Journal article published in 2021 by Marie Warrer Munch, M. W. Munch, K. la Cour, Sheila Nainan Myatra, B. Kumar Tirupakuzhi Vijayaraghavan, Sanjith Saseedharan, Thomas Benfield, Rebecka Rubenson Wahlin, R. R. Wahlin, Bodil Steen Rasmussen, B. S. Rasmussen, Anne Sofie Andreasen, Lone M. Poulsen, L. M. Poulsen, Luca Cioccari and other authors.

This paper was not found in any repository, but could be made available legally by the author.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle

Preprint: archiving allowed

Upload

Red circle

Postprint: archiving forbidden

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO